CN105602479A - 含封存型过氧化物的抗微生物水胶体敷料及其制备 - Google Patents
含封存型过氧化物的抗微生物水胶体敷料及其制备 Download PDFInfo
- Publication number
- CN105602479A CN105602479A CN201510780205.0A CN201510780205A CN105602479A CN 105602479 A CN105602479 A CN 105602479A CN 201510780205 A CN201510780205 A CN 201510780205A CN 105602479 A CN105602479 A CN 105602479A
- Authority
- CN
- China
- Prior art keywords
- peroxide
- composition
- water
- adhesive
- antimicrobial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002978 peroxides Chemical class 0.000 title claims abstract description 66
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 25
- 239000000416 hydrocolloid Substances 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title description 17
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 239000004599 antimicrobial Substances 0.000 claims abstract 2
- 239000000853 adhesive Substances 0.000 claims description 48
- 230000001070 adhesive effect Effects 0.000 claims description 48
- 239000000463 material Substances 0.000 claims description 28
- 239000004821 Contact adhesive Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 12
- 229920002367 Polyisobutene Polymers 0.000 claims description 11
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 10
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 10
- 206010021639 Incontinence Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 229920001169 thermoplastic Polymers 0.000 claims description 7
- 239000004416 thermosoftening plastic Substances 0.000 claims description 7
- 239000003292 glue Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- -1 styrene free radical Chemical class 0.000 claims description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229920000247 superabsorbent polymer Polymers 0.000 claims description 3
- 229920003169 water-soluble polymer Polymers 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- 240000001058 Sterculia urens Species 0.000 claims description 2
- 235000015125 Sterculia urens Nutrition 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229920005549 butyl rubber Polymers 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 229920001083 polybutene Polymers 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 230000008591 skin barrier function Effects 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000002550 fecal effect Effects 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 abstract description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 18
- 206010052428 Wound Diseases 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 229920001971 elastomer Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 101710171229 Peroxidase 12 Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920003049 isoprene rubber Polymers 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 206010029803 Nosocomial infection Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 239000007767 bonding agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001998 anti-microbiological effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- NKKRGHPYUUTNBF-UHFFFAOYSA-N benzene 2-methylbuta-1,3-diene Chemical compound CC(=C)C=C.C1=CC=CC=C1 NKKRGHPYUUTNBF-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000007613 slurry method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- HOWHQWFXSLOJEF-MGZLOUMQSA-N systemin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]2N(CCC2)C(=O)[C@H]2N(CCC2)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)CCC1 HOWHQWFXSLOJEF-MGZLOUMQSA-N 0.000 description 1
- 108010050014 systemin Proteins 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
- A61L15/585—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J123/00—Adhesives based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Adhesives based on derivatives of such polymers
- C09J123/02—Adhesives based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Adhesives based on derivatives of such polymers not modified by chemical after-treatment
- C09J123/18—Homopolymers or copolymers of hydrocarbons having four or more carbon atoms
- C09J123/20—Homopolymers or copolymers of hydrocarbons having four or more carbon atoms having four to nine carbon atoms
- C09J123/22—Copolymers of isobutene; Butyl rubber ; Homo- or copolymers of other iso-olefines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/11—Peroxy compounds, peroxides, e.g. hydrogen peroxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Abstract
本公开提供了包括封存型过氧化物源的抗微生物压敏粘合剂组合物和引入这样的组合物的器件。
Description
相关申请的交叉引用
不适用
关于联邦资助的研究和开发的引用
不适用
序列表
不适用
背景
发明领域
本公开涉及通过粘合剂与人体连接的重度创伤护理、失禁护理、导管固定物和造瘘器件。所述粘合剂是加入封存型过氧化物作为抗微生物剂的生物医学聚合物材料。
背景技术
重度创伤护理、失禁护理和造瘘护理器件在市场上是公知的。通常，这些器件经由对皮肤友好的粘合剂(诸如水胶体、丙烯酸系聚合物、硅酮等)连接。
例如，美国专利号4,551,490公开了特别适用于失禁、造瘘护理、创伤护理和烧伤护理敷料领域的压敏粘合剂组合物。类似地，其它现有技术器件，诸如美国专利号3,339,546、3,612,053、4,166,051、4,184,635、4,192,785、4,231,369、4,393,150、4,393,080、4,496,357、4,743,499、5,492,943和6,143,798中所公开的那些，同样也公开了这样的组合物。
包括过氧化物的超强吸收材料在美国专利公开号2010/0247615中披露。该公开涉及聚合组合物和抗微生物组合物，它们组合形成在尿布和其它卫生产品中使用的抗微生物超强吸收聚合物。
抗微生物压敏粘合剂及其用途也是已知的并且在美国专利号5,569,207、5,681,579、6,468,521、5,554,106和6,884,920中描述。
发明内容
本公开基于以下发现：与聚合物、低聚物和/或基质(matrices)结合的过氧化物可保持抗微生物功效，并且这些基材(substrates)用作过氧化物物种的稳定剂。因此，过氧化物浓度可被显著降低，从而使在将过氧化物施用于开放创伤时通常所发现的有害作用最小化。另外，这些被稳定的活性过氧化物物种可与典型水胶体材料一起配制以产生对皮肤友好的压敏粘合剂，从而使粘合剂内的生物负载最小化并提供卫生(hygienic)环境。
通常，本公开中的抗微生物水胶体层压体包括在两层或更多层基材之间的粘合剂挤出物质、防粘衬里或层压衬里。随后的中间体被转变、剪切或变形以产生抗微生物创伤护理敷料、创伤护理泡沫、造瘘器件、失禁粘合剂、固定(secure)导管的器件等。
在一个方面，抗微生物压敏粘合剂组合物包括封存型过氧化物源。
在另一方面，粘合器件包括具有一定量过氧化物的粘着材料。所述过氧化物的量足以在粘着材料中提供至少0.05％的活性过氧化物。
在第三方面，压敏粘合剂组合物包括约2wt％至约45wt％的一种或更多种聚异丁烯或者一种或更多种聚异丁烯与丁基橡胶的掺合物、约0.01wt％至约40wt％的矿物油、约1.0wt％至约30wt％的一种或更多种苯乙烯自由基型或嵌段型共聚物、约10wt％至约65wt％的一种或更多种水溶性水胶体胶、至多约15wt％的一种或更多种水可溶胀的粘着增强剂、约2.5wt％至约20wt％的增粘剂、约0.01wt％至约30wt％的超强吸收聚合物、约0.01wt％至约10wt％的金属盐、约0.01wt％至约2.0wt％的抗氧化剂和约0.01wt％至约10wt％的过氧化物。所述水溶性水胶体胶和水可溶胀的粘着增强剂共同以组合物的约15wt％至约65wt％存在。
附图说明
图1描绘了将1″粘性贴片(30密耳厚)置于涂有大肠杆菌的板上以测试由其所致的抑制区的结果。图1A＝0.05％过氧化物在粘合剂制剂中。图1B＝0.10％过氧化物在粘合剂制剂中。图1C＝0.20％过氧化物在粘合剂制剂中。图1D＝0.40％过氧化物在粘合剂制剂中。图1E＝0.80％过氧化物在粘合剂制剂中。图1F＝2.00％过氧化物在粘合剂制剂中；
图2描绘了将1″粘性贴片(30密耳厚)置于涂有MRSA的板上以测试由其所致的抑制区的结果。图2A＝0.05％过氧化物在粘合剂制剂中。图2B＝0.10％过氧化物在粘合剂制剂中。图2C＝0.20％过氧化物在粘合剂制剂中。图2D＝0.40％过氧化物在粘合剂制剂中。图2E＝0.80％过氧化物在粘合剂制剂中。图2F＝2.00％过氧化物在粘合剂制剂中；
图3描绘了将1″粘性贴片(30密耳厚)置于涂有MRSA的板上以测试由其所致的抑制区的结果。所述粘合剂不含过氧化物(对照物)；
图4描绘了加入根据一个实施方式的金属盐过氧化物超强吸收聚合物粘合剂制剂的器件；和
图5描绘了加入根据一个实施方式的金属盐过氧化物超强吸收聚合物粘合剂制剂的坯料(blank)。
具体实施方式
存在许多减少微生物增殖并减少医院获得性感染的公知的现有技术创伤用抗微生物粘合剂组合物，诸如包括抗菌剂和消毒剂的那些。然而，本公开提供了包含封存型稳定过氧化物的压敏粘合剂的组合物。这些新型组合物可以有利的效果用作抗微生物压敏粘合剂、创伤治疗物(诸如水胶体敷料或泡沫敷料)和/或用于造瘘和失禁应用的抗微生物治疗物。
创伤床自身提供了细菌和其它微生物可在其中繁盛的有吸引力的环境，这使得正常创伤痊愈复杂化。因此，用抗生素或抗微生物剂处理创伤以最小化感染将是合乎逻辑的治疗。然而，存在许多与抗生素和抗微生物剂的临床使用相关的潜在不利影响，诸如过敏反应、重金属中毒和增殖组织破坏。这些不利影响可被实现的程度通常取决于所施用的抗微生物剂的浓度。抗生素的一项重要不利副作用是抗生素耐药性微生物(例如MRSA)的出现。抗生素耐药性病原体的出现对控制感染来说是严重威胁，并且提供了开发设计为有效预防和治疗细菌感染的新型疗法的可信理由。
一些抗微生物治疗物包括含银凝胶、含重金属的化合物、过氧化氢溶液及其它天然物质。银离子破坏细菌酶并因此抑制细菌生长。银离子与酶和蛋白中的硫醇基团(硫或-SH基团)的相互作用据信在其抗微生物作用中起重要作用。关键酶和蛋白的破坏可导致细胞分化受抑制、细胞包膜受损和细菌细胞溶解。类似地，高水平的过氧化氢具有毒性效果。过氧化氢通过氧化细胞组分而抑制细菌生长。反应性氧物种结合或改性DNA、蛋白和脂质。然而，在高浓度下，过氧化氢通过影响结缔组织形成而降低创伤愈合以及通过基质金属蛋白酶水平升高而降低创伤闭合。使用过氧化氢的其它障碍在于其通常以溶液使用，在溶液中其是不稳定的并且对于广谱的抗微生物用途来说难以提供持续递送系统。
在超过30年间，诸如水胶体的压敏粘合剂已被用于创伤的安全有效治疗以及造瘘器件、导管和失禁器件的连接。水胶体是闭合性吸湿敷料，其吸收创伤渗出液，形成凝胶，并且已显示具有减少因捕获凝胶基质中的细菌而致交叉污染的机会的有益效果。在基质中添加抗微生物剂可在敷料中提供额外的细菌生长控制，从而进一步减少交叉污染发生率和敷料内的生物负载。
在过去十年间，FDA已批准和清除了若干含银压敏粘合剂，它们与这些市场上的非-抗微生物器件相当。抗微生物银敷料已反复显示为安全和有效的，无论是否对创伤床有显著的潜在细胞毒性效果。尽管如此，在过去数年间，银-基压敏粘合剂已被放弃，这可归因于生产成本高、缺少更高赔付以及对创伤愈合的潜在负面影响。
目前，缺乏有效的压敏粘合剂中的抗微生物剂在患者护理中产生显著缺口，并且造成严重并发症的威胁。护理者没有对皮肤友好的抗微生物粘合剂来辅助患者的重度创伤愈合或固定另一个医学器件。此外，在应用粘合剂之前应用常规局部抗生素可能是禁忌的(counterindicated)或以其它方式降低粘合剂的有效性。抗微生物水胶体将使微生物增殖和交叉污染的风险最小化。
如上所述，高浓度过氧化物的不受控的应用可能对增殖创伤床是有害的。然而，具有受控释放的稳定的过氧化氢可以较低浓度施用，同时保持其抗微生物功效并提供额外的利益。在较低浓度下，过氧化氢促进创伤闭合，提高血管形成，并且保持正常的MMP水平。近来的研究已证实过氧化氢可促进神经轴突再生。在皮肤受伤之后，细胞产生过氧化氢以吸引中性粒细胞，这增加了中性粒细胞活性并促进健康的创伤床。通过用催化酶处理来去除创伤中低水平的天然过氧化氢的研究显示了降低的创伤愈合和降低的血管形成。
本发明的抗微生物压敏粘合剂组合物为医药领域中的用途提供了平台以减少医院获得性感染，减少与皮肤连接的器件下的生物负载，提高指定疗法的清洁性，并且减少与许多应用相关的气味。
可用于过氧化物封存的材料包括可施加给有此需要的受试对象的任何合适的材料。在一个实施方式中，考虑了超强吸收材料。所考虑的超强吸收材料(SAMs)包括那些可溶性、不可溶的、粉末基的、成膜的、成凝胶的、复合物、共聚物、纤维等的物质。所考虑的具体SAMs包括聚丙烯酸酯，藻酸盐，纤维素衍生物(诸如羧甲基纤维素)，或者含有与过氧化物或另一种反应性中间体结合并与含过氧化物组分形成桥的反应性基团的任何聚合物。适合用于本公开中的其它反应性中间体包括具有将过氧化物封存于稳定组合物中的SAMs的能力的盐或其他组分或化合物。适合用于本公开中的盐例如包括锌、铜、银、锆或锰的盐。
可用的过氧化物源可包括过氧化氢、过氧化苯甲酰或形式为稳定的抗微生物和免疫刺激系统的产生过氧化物的装置。例如，系统可包括氧化还原酶、氧化还原酶底物和其它导致产生可在粘合剂物质生产之前或期间封存在粘合剂物质中的稳定过氧化物的辅因子。
本公开中的粘合剂制剂可具有很多种应用。例如，本公开的粘合剂制剂可与提供湿润创伤愈合环境的创伤护理器件协同使用。据信所考虑的包括封存型过氧化物化合物的水胶体、藻酸盐、泡沫和带边敷料通过减少细菌负载而有益于患者，并且有可能提供愈合速度和清创术方面的额外利益。
例如，收集废物并经由所考虑的水胶体粘合剂与身体连接的造瘘器件将具有若干患者利益。这些带有封存型过氧化物的造瘘器件将减少气味，提高卫生，并且减少通常与这些器件的使用相关的细菌和真菌负载。因此，包括所公开的粘合剂的一件式造瘘系统、两件式收集系统和尿道造口收集系统将有益于患者。除了收集器件本身之外，包括所公开的粘合剂的其它造瘘附件，诸如贴片、密封剂、密封环和粘合带，将产生有益于使用者的连续系统。
在另一个例子中，导管用于治疗内科疾病，并且在临床/医院环境中是用于患者护理的整体构件。在所有情况中，传统的粘合带用于将导管固定于身体。本申请中公开的粘合剂将在臀部皮肤周围和其上提供抗微生物环境，由此减少交叉感染和潜在危及生命的并发症。在外部导管和失禁器件方面，所公开的粘合剂将提供清洁和卫生的环境以最小化气味并以对皮肤友好的粘合剂减少对皮肤的其它伤害。因此，用于固定这些器件的胶带或绷带可用本申请中公开的粘合剂制成。具体例子在下文的实施例中讨论。
实施例
实施例1–所考虑的粘合剂的配制
水胶体粘合剂配方是公知的，但包含抗微生物剂、收敛剂或非银的广谱药剂的水胶体则不是。通常，水胶体制剂及制造与常用的抗微生物剂或广谱药剂是不相容的，因为其较不稳定。我们的目标是开发能采用过氧化物作为广谱药剂的水胶体制剂。由于过氧化物的不稳定特性、粘合剂中的高分子量组分以及典型制造过程的温度曲线，我们不相信我们将会成功。
水胶体粘合剂利用了连续相和不连续相。连续相可包含各种量和各种组合的永久粘性压敏粘合剂、含苯乙烯的热塑性高弹体、液体橡胶、低分子量聚异丁烯、稳定剂和低分子量液体聚丁烯的混合物。当热塑性高弹体被用作结合剂(integratingagents)时，其将其它高分子量组分固定(hold)在一起，超过350的高温是混合这些组分所需的。
不连续相包含一种或更多种水溶性和/或水可溶胀的吸收聚合物(SAP)，诸如羧甲基纤维素(CMC)、锌、水胶体胶等。一旦连续相均匀，则立刻将不连续组分全部加入，或者按时间方式以相应的滴状物在混合物温度下加入。如果不连续相过热，则添加含过氧化物材料会导致不可控的放热反应并导致粘合剂失效和抗微生物功效丧失。
合适的热塑性含苯乙烯高弹体包括基于苯乙烯-丁二烯、苯乙烯-异戊二烯或苯乙烯-乙烯-丁烯的嵌段共聚物。还有，丁二烯与苯乙烯的低苯乙烯合成共聚物通常被称为SBR橡胶，其可用作热塑性高弹体。高弹体可由线性或径向的A-B-A嵌段共聚物或者这些A-B-A共聚物与简单A-B嵌段共聚物的混合物组成。最终的粘合剂组合物可包含约1wt％至约30wt％的该组分。
本文所考虑的液体橡胶包括合成液体异戊二烯橡胶、羟基封端的合成液体异戊二烯橡胶、氢化液体异戊二烯橡胶、液体异戊二烯-苯乙烯共聚物、液体异戊二烯-丁二烯共聚物和液体丁二烯-苯乙烯共聚物。液体橡胶通常具有约25,000至约50,000的分子量。优选地，液体橡胶具有低于约-50℃的玻璃化转变温度，以及在38℃下约500至约10,000泊的熔体粘度。本领域中已知的其它液体橡胶可用于连续相中。最终的粘合剂组合物应包含约10wt％至约55wt％的这些组分。
聚异丁烯组分可包括得自ExxonChemicalCorporation的LM系列的聚异丁烯，其具有约35,000至约70,000范围内的平均分子量和约20,000至约140,000mPa范围内的粘度。低分子量聚丁烯组分可包括得自BP的Hyvis系列材料和得自Exxon的Parapol系列产品，并且可具有约1000至约3000范围的分子量。最终的粘合剂组合物应包含约2wt％至约45wt％的这些组分。
其它成分诸如合适的加工稳定剂也可被包含在热熔性粘合剂组分中。例子包括1010，其是四(3-(3,5-二-叔丁基-4-羟苯基)丙酸)季戊四醇酯。另外，增粘剂、油和增塑剂可被添加到连续相以改进粘性和优化粘附特性。最终的粘合剂组合物可包含约0.5wt％至约35wt％的这些组分。
不连续相可包括一种或更多种可在水溶液(包括所有身体分泌物)中溶胀的亲水性吸水聚合物。一种或更多种可溶胀聚合可以存在。合适的可溶胀聚合物包括，例如，交联羧甲基纤维素钠或结晶羧甲基纤维素钠。可溶胀聚合物也可为“超强吸收”材料，诸如聚丙烯酸淀粉钠。合适的水溶性聚合物可包括羧甲基纤维素钠、果胶、明胶、瓜尔胶、阿拉伯树胶、槐豆胶、胶原、刺梧桐树胶、锌、金属盐和淀粉等。不连续相通常不应超过粘合剂总重的约65％，并且可包括可溶和/或不溶性吸收剂的任何组合。
粘合剂组合物可如下制备。将热塑性高弹体、聚异丁烯(PIBs)和液体橡胶组分在合适的混合器中掺和在一起，通常为带有挤出机排放(extruderdischarge)的西格马桨叶混合器(sigmablademixer)。将混合器加热到设为135℃至170℃。约1％的合适稳定剂(诸如1010)应在此阶段添加。一旦热塑性高弹体、PIBs、液体橡胶和稳定剂掺和，将混合器温度降低至75℃。在特定冷却温度设定点，油135℃和110℃、增粘剂110℃和95℃以及增塑剂105℃和90℃按时间方式添加。一旦混合物掺和并充分冷却到约75℃至99℃之间，将不连续相的粉末状水胶体成分、金属盐、过氧化物掺合物等添加到混合器。我们已发现SAP、金属盐和过氧化物的稳定组合可在低于99℃的温度与其它不连续相组分一起添加而不会丧失过氧化物抗微生物活性。这些被混合至匀，并且将混合器温度降至约80℃。在此阶段，完全混合的物质被从混合器中取出。所述物质被挤出或压制成所需厚度，同时将其层压至合适基材上以便在需要时模切成型。
在下表1中呈现了若干种在wt％浓度上变化的粘合剂制剂。应注意这些制剂是代表性的，并且不包含所有预期组合。
表1
实施例2–不同金属盐过氧化物SAP的抗菌功效测试。
为确认上述制剂的功效，我们测试了每种制剂以30密耳厚的1”模切圆环杀死大肠杆菌(E.coli)和MRSA的能力。每个样品针对大肠杆菌和MRSA使用琼脂浆法(agarslurrymethod)测试。这些样品的培养液水平高出6logs(以超过1x106细胞/板接种)。
随后，将每种制剂的一个1″粘性贴片(30密耳厚)(见表2)置于分别涂有大肠杆菌和MRSA的板上以测试使用每种制剂所发现的抑制区(zoneofinhibition)。这些测试于37℃温育24小时，随后拍照。参考下表3和图1A-F及2A-F来看分别针对EC和MRSA的功效结果。
表2
| 粘合剂中活性物的％ | 添加的活性SAP的％ |
| A)过氧化物0.05％ | 0.5％活性(含活性过氧化物的混合SAP，MSPO) |
| B)过氧化物0.10％ | 1％活性MSPO |
| C)过氧化物0.20％ | 2％活性MSPO |
| D)过氧化物0.40％ | 4％活性MSPO |
| E)过氧化物0.80％ | 8％活性MSPO |
| F)过氧化物2.00％ | 20％活性MSPO |
表3
| 平均 | 平均 | |
| Log降低 | Log降低 | |
| 样品对EC | 过夜 | t＝0 |
| A)过氧化物0.05％ | 7.70*±0.00 | 6.13*±0.00 |
| B)过氧化物0.10％ | 7.70*±0.00 | 6.13*±0.00 |
| C)过氧化物0.20％ | 7.70*±0.00 | 6.13*±0.00 |
| D)过氧化物0.40％ | 7.70*±0.00 | 6.13*±0.00 |
| E)过氧化物0.80％ | 7.70*±0.00 | 6.13*±0.00 |
| F)过氧化物2.00％ | 7.70*±0.00 | 6.13*±0.00 |
| 平均 | 平均 | |
| Log降低 | Log降低 | |
| 样品对MRSA | 过夜 | t＝0 |
| A)过氧化物0.05％ | 5.81*±0.00 | 5.76*±0.00 |
| B)过氧化物0.10％ | 5.81*±0.00 | 5.76*±0.00 |
| C)过氧化物0.20％ | 5.81*±0.00 | 5.76*±0.00 |
| D)过氧化物0.40％ | 5.81*±0.00 | 5.76*±0.00 |
| E)过氧化物0.80％ | 5.81*±0.00 | 5.76*±0.00 |
| F)过氧化物2.00％ | 5.81*±0.00 | 5.76*±0.00 |
| *表示完全杀死 |
如表3中所见，所有样品显示对MRSA和大肠杆菌完全杀死。
围绕所述器件的抑制区可归因于活性MSPO浓度。相反，图3中所示的含有0％MSPO的对照物显示不抑制细菌生长。此外，图1A-F和2A-F的抑制区证实不同的金属盐过氧化物SAP制剂不仅杀死其所接触的细菌，而且它们在加入所述制剂的器件周围进一步产生保护区。因此，加入本发明制剂的本公开的器件将为使用该器件的受试对象提供改进的抗菌功能。
实施例3–对形成包含来自实施例1的粘合剂的绷带或其它器件的描述
图4中显示了所考虑的包括实施例1的粘合剂制剂的器件10的例子。器件10可包括中心部分12和周围部分14，所述中心部分12可为由例如纤维素材料或塑料材料制成的消毒纱布样材料或其它吸收性材料，且所述周围部分14可包括如本文所述的粘合剂制剂。或者可选地，中心部分12可构成金属盐过氧化物SAP制剂，且周围部分14可为衬底材料，诸如提供不粘表面的纤维素材料或塑料材料。在本文中可考虑额外的变动。器件10可具有任何尺寸，诸如，如所示的正方形构造，或者可为矩形、三角形、椭圆形、圆形等。
进一步预期器件10可通过印花和/或自动剪切器件进行定制设计，在所述印花和/或自动剪切器件中已经由计算机或类似界面针对具体目的的个性化尺寸进行了编程。类似地，预期了所考虑的粘合剂材料的坯料20，如图5中所示。坯料20可包括通过穿孔24界定的预先选择的剪裁图样22，并且可根据需要用于多种应用中。在本文中考虑了任何尺寸和/或形状的坯料20和剪裁图样22。坯料20还可包括一侧或两侧的不粘材料(例如，前片和后片)以允许在使用之前对该坯料进行无菌操作。
工业实用性
本文所述的制剂和器件有利地提供了对于通过粘合剂与人体连接的重度创伤护理物、失禁护理物、导管固定物和造瘘器件的改进。
参考前文描述很多种修改对于本领域技术人员来说是明显的。因此，本说明书应被解释为仅说明性的，并且为能使本领域技术人员制造和使用本发明并教导其最佳实施方式的目的进行阐述。保留对进入本申请范围内的所有修改的专有权利。所有专利和专利公开通过引用并入。
Claims (20)
1.一种抗微生物压敏粘合剂组合物，包含封存型过氧化物源。
2.如权利要求1所述的组合物，其中所述组合物包含水胶体。
3.如权利要求2所述的组合物，其中所述水胶体包括连续相和不连续相。
4.如权利要求3所述的组合物，其中所述连续相包括以下中的至少一种：永久粘性压敏粘合剂、含苯乙烯的热塑性高弹体、液体橡胶、低分子量聚异丁烯、稳定剂、低分子量液体聚丁烯、热塑性高弹体及其组合。
5.如权利要求4所述的组合物，其中所述热塑性高弹体将其它高分子量组分固定在一起。
6.如权利要求3所述的组合物，其中所述不连续相包括以下中的至少一种：水溶性聚合物、水可溶胀的吸收聚合物、锌、水胶体胶及其组合。
7.如权利要求6所述的组合物，其中所述水可溶胀的聚合物包括以下中的至少一种：交联羧甲基纤维素钠、结晶羧甲基纤维素钠及其组合。
8.如权利要求6所述的组合物，其中所述水溶性聚合物包括以下中的至少一种：羧甲基纤维素钠、果胶、明胶、瓜尔胶、阿拉伯树胶、槐豆胶、胶原、刺梧桐树胶、淀粉及其组合。
9.一种造瘘皮肤屏障，包含权利要求1的组合物。
10.如权利要求9所述的造瘘皮肤屏障，其中所述皮肤屏障阻止气味并提高造口周围的卫生。
11.失禁器件连接件，包含权利要求1的组合物。
12.如权利要求11所述的失禁器件，其中所述器件用于密封泄露、阻止气味、预防粪便污染和提高泌尿器官周围的卫生。
13.一种粘合器件，包含：
粘着材料，其包含一定量的过氧化物，其中所述过氧化物的量足以在所述粘着材料中提供至少0.05％的活性过氧化物。
14.如权利要求13所述的粘合器件，其中所述器件选自贴片、绷带和坯料。
15.如权利要求14所述的粘合器件，其中所述器件包括在其一侧上的不粘层。
16.如权利要求15所述的粘合器件，其中所述器件包含吸收材料。
17.如权利要求16所述的粘合器件，其中所述器件包含预先选择的剪裁图样。
18.如权利要求17所述的粘合器件17，其中所述剪裁图样具有以下中的至少一种：正方形、矩形、三角形、椭圆形或圆形。
19.一种压敏粘合剂组合物，包含：
约2wt％至约45wt％的一种或更多种聚异丁烯或者一种或更多种聚异丁烯与丁基橡胶的掺合物；
约0.01wt％至约40wt％的矿物油；
约1.0wt％至约30wt％的一种或更多种苯乙烯自由基型或嵌段型共聚物；
约10wt％至约65wt％的一种或更多种水溶性水胶体胶；
至多约15wt％的一种或更多种水可溶胀的粘着增强剂；
约2.5wt％至约20wt％的增粘剂；
约0.01wt％至约30wt％的超强吸收聚合物；
约0.01wt％至约10wt％的金属盐；
约0.01wt％至约2.0wt％的抗氧化剂；和
约0.01wt％至约10wt％的过氧化物，
其中所述水溶性水胶体胶和所述水可溶胀的粘着增强剂共同以所述组合物的约15wt％至约65wt％存在。
20.如权利要求19所述的压敏粘合剂组合物，其中所述组合物在24小时内显示大于5log的大肠杆菌或MRSA的减少。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110157929.5A CN112980354A (zh) | 2014-11-13 | 2015-11-13 | 含封存型过氧化物的抗微生物水胶体敷料及其制备 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/540,911 | 2014-11-13 | ||
| US14/540,911 US10485893B2 (en) | 2014-11-13 | 2014-11-13 | Antimicrobial hydrocolloid dressing containing sequestered peroxide and preparation thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110157929.5A Division CN112980354A (zh) | 2014-11-13 | 2015-11-13 | 含封存型过氧化物的抗微生物水胶体敷料及其制备 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105602479A true CN105602479A (zh) | 2016-05-25 |
Family
ID=54542103
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510780205.0A Pending CN105602479A (zh) | 2014-11-13 | 2015-11-13 | 含封存型过氧化物的抗微生物水胶体敷料及其制备 |
| CN202110157929.5A Pending CN112980354A (zh) | 2014-11-13 | 2015-11-13 | 含封存型过氧化物的抗微生物水胶体敷料及其制备 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110157929.5A Pending CN112980354A (zh) | 2014-11-13 | 2015-11-13 | 含封存型过氧化物的抗微生物水胶体敷料及其制备 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10485893B2 (zh) |
| EP (1) | EP3020423B1 (zh) |
| JP (1) | JP6645808B2 (zh) |
| CN (2) | CN105602479A (zh) |
| DK (1) | DK3020423T3 (zh) |
| ES (1) | ES2674487T3 (zh) |
| HU (1) | HUE038214T2 (zh) |
| PL (1) | PL3020423T3 (zh) |
| TR (1) | TR201807890T4 (zh) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
| GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
| GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
| US9526816B2 (en) | 2010-12-08 | 2016-12-27 | Convatec Technologies Inc. | Wound exudate monitor accessory |
| WO2012078781A1 (en) | 2010-12-08 | 2012-06-14 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
| GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
| GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
| KR20150099776A (ko) | 2012-12-20 | 2015-09-01 | 컨바텍 테크놀러지스 인크 | 화학적 개질된 셀룰로스 섬유의 처리 |
| KR20190008199A (ko) | 2016-03-30 | 2019-01-23 | 시노보 게엠베하 | 상처에서 미생물 감염의 검출 방법 |
| CN109310528B (zh) | 2016-03-30 | 2021-07-20 | 康沃特克科技公司 | 检测伤口中的微生物感染 |
| HUE055926T2 (hu) | 2016-05-04 | 2022-01-28 | Coloplast As | Ragasztólap egy semlegesítõ mátrixszal |
| EP3481360B1 (en) | 2016-07-08 | 2022-03-09 | ConvaTec Technologies Inc. | Fluid flow sensing |
| WO2018009873A1 (en) | 2016-07-08 | 2018-01-11 | Convatec Technologies Inc. | Fluid collection apparatus |
| ES2882336T3 (es) | 2016-07-08 | 2021-12-01 | Convatec Technologies Inc | Sistema flexible de presión negativa |
| USD821589S1 (en) | 2016-12-30 | 2018-06-26 | Euromed, Inc. | Heel adhesive patch |
| USD824526S1 (en) | 2016-12-30 | 2018-07-31 | Euromed, Inc. | Adhesive patch system |
| EP3706673B1 (en) | 2017-11-08 | 2024-04-03 | Coloplast A/S | An adhesive wafer with a neutralizer matrix |
| BR112020008416A2 (pt) | 2017-11-08 | 2020-11-17 | Coloplast A/S | wafer adesivo para um dispositivo de ostomia, e, aparelho de ostomia. |
| US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
| US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
| WO2024025764A1 (en) * | 2022-07-28 | 2024-02-01 | EnvirOx, LLC | Stabilization of hydrogen peroxide containing formulations with two-component synergistic stabilizers |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002013879A2 (en) * | 2000-08-16 | 2002-02-21 | Scapa Tapes N.A. | Calendered hydrocolloid dressing |
| US20060121100A1 (en) * | 2004-12-06 | 2006-06-08 | Opremcak E M | Bandage and method for vital bleaching of skin |
| CN102459747A (zh) * | 2009-06-08 | 2012-05-16 | 奎克-麦德技术公司 | 包含过氧化物的抗菌纺织物 |
| WO2012134770A1 (en) * | 2011-03-25 | 2012-10-04 | Avery Dennison Corporation | Honey composition |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3339546A (en) | 1963-12-13 | 1967-09-05 | Squibb & Sons Inc | Bandage for adhering to moist surfaces |
| US3612053A (en) | 1969-06-23 | 1971-10-12 | Minnesota Mining & Mfg | Ostomy sealing washer |
| US4184635A (en) | 1976-02-21 | 1980-01-22 | Bloomfield Edward J | Control units for heating systems |
| GB1576522A (en) | 1977-05-24 | 1980-10-08 | Colorplast International A S | Sealing material for ostomy devices |
| US4166051A (en) | 1977-06-08 | 1979-08-28 | E. R. Squibb & Sons, Inc. | Ostomy composition |
| US4192785A (en) | 1977-06-08 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Ostomy adhesive |
| US4201211A (en) * | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| US4496357A (en) | 1981-06-10 | 1985-01-29 | Hollister Incorporated | Skin barrier composition |
| US4393080A (en) | 1981-12-24 | 1983-07-12 | E. R. Squibb & Sons, Inc. | Adhesive compositions |
| US4393150A (en) | 1982-05-07 | 1983-07-12 | Stanley Kresner | Adhesive bandage material |
| US4551490A (en) | 1983-06-27 | 1985-11-05 | E. R. Squibb & Sons, Inc. | Adhesive composition resistant to biological fluids |
| JPS6242920A (ja) | 1985-08-20 | 1987-02-24 | Nitto Electric Ind Co Ltd | 医薬製剤 |
| EP0252076A1 (en) * | 1985-12-12 | 1988-01-13 | Flexcon Company, Inc. | Transdermal methods and adhesives |
| US4743499A (en) | 1987-05-20 | 1988-05-10 | Variseal Corporation | Hydrocolloid laminate |
| US5681579A (en) | 1993-03-22 | 1997-10-28 | E.R. Squibb & Sons, Inc. | Polymeric support wound dressing |
| US5492943A (en) | 1994-06-20 | 1996-02-20 | Hollister Incorporated | Adhesive skin barrier composition for ostomy appliance |
| US5569207A (en) | 1994-10-13 | 1996-10-29 | Quinton Instrument Company | Hydrocolloid dressing |
| US5554106A (en) | 1994-10-13 | 1996-09-10 | Quinton Instrument Company | Hydrocolloid exit site dressing |
| AU5153399A (en) | 1998-08-14 | 2000-03-06 | Coloplast A/S | Stabilised compositions having antibacterial activity |
| US6143798A (en) | 1999-01-11 | 2000-11-07 | Jentec, Inc. | Wound dressing |
| US6884920B2 (en) | 2001-03-02 | 2005-04-26 | George Medical, L.L.C. | Hydrocolloid window catheter dressing and a method for making and using the same |
| US8728445B2 (en) | 2001-05-01 | 2014-05-20 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel Compositions |
| CN101039706A (zh) * | 2004-08-05 | 2007-09-19 | 考里安国际公司 | 粘合剂组合物 |
| US7481974B2 (en) | 2005-02-17 | 2009-01-27 | Charles Sizer | Method and apparatus for sterilizing containers |
| CN102405063B (zh) | 2009-02-18 | 2015-12-09 | 奎克-麦德技术公司 | 含有过氧化物的超吸收材料 |
-
2014
- 2014-11-13 US US14/540,911 patent/US10485893B2/en active Active
-
2015
- 2015-11-12 JP JP2015221864A patent/JP6645808B2/ja not_active Expired - Fee Related
- 2015-11-13 HU HUE15194510A patent/HUE038214T2/hu unknown
- 2015-11-13 TR TR2018/07890T patent/TR201807890T4/tr unknown
- 2015-11-13 EP EP15194510.2A patent/EP3020423B1/en active Active
- 2015-11-13 PL PL15194510T patent/PL3020423T3/pl unknown
- 2015-11-13 CN CN201510780205.0A patent/CN105602479A/zh active Pending
- 2015-11-13 DK DK15194510.2T patent/DK3020423T3/en active
- 2015-11-13 ES ES15194510.2T patent/ES2674487T3/es active Active
- 2015-11-13 CN CN202110157929.5A patent/CN112980354A/zh active Pending
-
2019
- 2019-11-25 US US16/693,687 patent/US11027042B2/en active Active
-
2021
- 2021-05-19 US US17/324,295 patent/US11590257B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002013879A2 (en) * | 2000-08-16 | 2002-02-21 | Scapa Tapes N.A. | Calendered hydrocolloid dressing |
| US20060121100A1 (en) * | 2004-12-06 | 2006-06-08 | Opremcak E M | Bandage and method for vital bleaching of skin |
| CN102459747A (zh) * | 2009-06-08 | 2012-05-16 | 奎克-麦德技术公司 | 包含过氧化物的抗菌纺织物 |
| WO2012134770A1 (en) * | 2011-03-25 | 2012-10-04 | Avery Dennison Corporation | Honey composition |
Also Published As
| Publication number | Publication date |
|---|---|
| US11027042B2 (en) | 2021-06-08 |
| HUE038214T2 (hu) | 2018-10-29 |
| ES2674487T3 (es) | 2018-07-02 |
| JP6645808B2 (ja) | 2020-02-14 |
| US20160136323A1 (en) | 2016-05-19 |
| EP3020423B1 (en) | 2018-04-11 |
| EP3020423A1 (en) | 2016-05-18 |
| US20210338884A1 (en) | 2021-11-04 |
| US20200093954A1 (en) | 2020-03-26 |
| DK3020423T3 (en) | 2018-07-23 |
| TR201807890T4 (tr) | 2018-06-21 |
| CN112980354A (zh) | 2021-06-18 |
| US11590257B2 (en) | 2023-02-28 |
| JP2016120276A (ja) | 2016-07-07 |
| US10485893B2 (en) | 2019-11-26 |
| PL3020423T3 (pl) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105602479A (zh) | 含封存型过氧化物的抗微生物水胶体敷料及其制备 | |
| EP0340945B1 (en) | Hydrocolloid/adhesive composition | |
| EP1237561B1 (en) | Medical dressings comprising gelled honey | |
| CN100471528C (zh) | 具有促进伤口愈合、抗菌功能的液体伤口敷料 | |
| ES2307331T3 (es) | Masa adhesivo hidrocoloide utilizable con fines medicos. | |
| JP3628809B2 (ja) | 薬剤徐放性医療用配合物及びその製造方法 | |
| DE69735550T3 (de) | Ostomievorrichtung | |
| CZ91099A3 (cs) | Hydrofilní adhezivní hmota a její použití | |
| EP0055023A2 (en) | Antiseptic containing adhesive composition | |
| DE60001980T2 (de) | Flüssigkeit absorbierende, adhesive hydrokolloide zusammensetzungen | |
| WO2000053690A1 (fr) | Nouvelle masse adhesive hydrocolloide presentant une meilleure resistance a la degradation de sa capacite d'absorption apres radiosterilisation | |
| CN103495174B (zh) | 用于治疗浅表性皮肤损伤的多效外用制剂及其用途 | |
| Hampton | Malodorous fungating wounds: how dressings alleviate symptoms | |
| Fialho et al. | Exploring innovative adhesive approaches to manage medical adhesive-related skin injuries (MARSI) | |
| JPH1189926A (ja) | ハイドロコロイドドレッシング材及び当該ハイドロコロイドドレッシング材を用いた機能性外用材 | |
| CN114306720A (zh) | 一种含有芦荟凝胶的伤口敷料及其制备方法 | |
| ZA200204615B (en) | Use of honey in medical dressings. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160525 |
|
| RJ01 | Rejection of invention patent application after publication |